Answers are grounded in this paper and cite their sources.
// Tapan Mahendra Kadia 1 , Hagop M. Kantarjian 1 and Marina Konopleva 1 1 The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Correspondence to: Tapan Mahendra Kadia, email: tkadia@mdanderson.org Keywords: AML; BCL-2; MCL-1; flavopiridol; alvocidib Received: November 08, 2018 Accepted: December 16, 2018 Published: February 08, 2019 ABSTRACT Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults, affecting approximately 21,000 people annually (nearly 11,000 deaths) in the United States. B-cell lymphoma 2 (BCL-2) family proteins, notably myeloid cell leukemia-1 (MCL-1), have been associated with both the development and persistence of AML. MCL-1 is one of the predominant BCL-2 family members expressed in samples from patients with untreated AML. MCL-1 is a critical cell survival factor for cancer and contributes to chemotherapy resistance by directly affecting cell death pathways. Here, we review the role of MCL-1 in AML and the mechanisms by which the potent cyclin-dependent kinase 9 inhibitor alvocidib, through regulation of MCL-1, may serve as a rational therapeutic approach against the disease.
No takes yet. Share an insight, caveat, or question.
Kadia et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: